AXS-02
Phase
Phase3Study status
UnknownView details
Axsome Therapeutics, Inc.
IndicationOsteoarthritis, Knee
Estimated study completion2020-12
Cash and cash equivalents · Restricted cash and marketable securities excluded
Cash verified Nov 16, 2026
No verified development in tracked sources.
Next verified event · Clinical readout window
Binge Eating Disorder
Phase 3
Postponed to a later window
Previous: Q4 2026 · quarter precision
Announced Aug 10, 2026
Previous official sourceBinge Eating Disorder: Axsome is conducting the ENGAGE study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in BED. The Company anticipates topline results from the ENGAGE Phase 3 trial in the fourth quarter of 2026.
Current: Q1 2027 · quarter precision
Announced Nov 2, 2026
Current official sourceBinge Eating Disorder: Axsome is conducting the ENGAGE study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in BED. Target enrollment in the trial has been reached, and the Company anticipates topline results in the first quarter of 2027.
Announced Nov 2, 2026 · Announced window
Official announcementBinge Eating Disorder: Axsome is conducting the ENGAGE study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in BED. Target enrollment in the trial has been reached, and the Company anticipates topline results in the first quarter of 2027.
FDA target date
cataplexy in narcolepsy
Announced Nov 2, 2026
Official announcementNarcolepsy: Axsome’s NDA for AXS-12 for the treatment of cataplexy in narcolepsy is currently under review by the FDA. The PDUFA target action date is May 1, 2027.
Clinical readout window
children with ADHD
Phase 3
Announced Nov 2, 2026 · Announced window
Official announcementAttention Deficit Hyperactivity Disorder: Axsome is conducting the FOCUS-2 and FOCUS-3 Phase 3, randomized, double-blind, placebo-controlled, multicenter trials evaluating the efficacy and safety of solriamfetol as a treatment for children and adolescents in ADHD, respectively. The Company anticipates topline results from both studies in the second half of 2027.
Clinical readout window
adolescents with ADHD
Phase 3
Announced Nov 2, 2026 · Announced window
Official announcementAttention Deficit Hyperactivity Disorder: Axsome is conducting the FOCUS-2 and FOCUS-3 Phase 3, randomized, double-blind, placebo-controlled, multicenter trials evaluating the efficacy and safety of solriamfetol as a treatment for children and adolescents in ADHD, respectively. The Company anticipates topline results from both studies in the second half of 2027.
Clinical readout window
smoking cessation
Phase 3
Announced Nov 2, 2026 · Announced window
Official announcementSmoking Cessation: In August 2026, Axsome initiated the SUMMIT study, a Phase 3, randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 for the treatment of smoking cessation. The Company anticipates topline results from the SUMMIT Phase 3 trial in the second half of 2027.
Clinical readout window
Shift Work Disorder
Phase 3
Narrower timing window
Previous: 2027 · year precision
Announced Aug 10, 2026
Previous official sourceShift Work Disorder: Axsome is conducting the SUSTAIN study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in SWD in adults. The Company anticipates topline results from the SUSTAIN Phase 3 trial in 2027.
Current: H2 2027 · half precision
Announced Nov 2, 2026
Current official sourceShift Work Disorder: Axsome is conducting the SUSTAIN study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in SWD in adults. The Company anticipates topline results from SUSTAIN in the second half of 2027.
Announced Nov 2, 2026 · Announced window
Official announcementShift Work Disorder: Axsome is conducting the SUSTAIN study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in SWD in adults. The Company anticipates topline results from SUSTAIN in the second half of 2027.
20 programs · 36 verified studies
| Company | Drug | Indication | Phase | Study status | Timing | Registry |
|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics, Inc. | AXS-02 | Osteoarthritis, Knee | Phase3 | Unknown | Estimated study completion2020-12 | NCT02746068 |
| AXSM Axsome Therapeutics, Inc. | AXS-02 (oral zoledronate) | Complex Regional Pain Syndrome; Reflex Sympathetic Dystrophy | Phase3 | Unknown | Estimated study completion2019-01 | NCT02504008 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Treatment Resistant Major Depressive Disorder | Phase3 | Completed | Actual study completion2020-03-20 | NCT02741791 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation,Psychomotor | Phase2 / Phase3 | Completed | Actual study completion2020-04-17 | NCT03226522 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Major Depressive Disorder | Phase2 | Completed | Actual study completion2019-01-07 | NCT03595579 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Depression; Major Depressive Disorder | Phase3 | Completed | Actual study completion2019-12-05 | NCT04019704 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Treatment Resistant Depression; Major Depressive Disorder | Phase2 | Completed | Actual study completion2021-07-30 | NCT04608396 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation,Psychomotor | Phase3 | Completed | Actual study completion2022-11-21 | NCT04797715 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Major Depressive Disorder; Treatment Resistant Depression | Phase2 | Unknown | Estimated study completion2021-07 | NCT04971291 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation | Phase3 | Completed | Actual study completion2024-12-21 | NCT05557409 |
Phase
Phase3Study status
UnknownAxsome Therapeutics, Inc.
IndicationOsteoarthritis, Knee
Estimated study completion2020-12
Phase
Phase3Study status
UnknownAxsome Therapeutics, Inc.
IndicationComplex Regional Pain Syndrome; Reflex Sympathetic Dystrophy
Estimated study completion2019-01
Phase
Phase3Study status
CompletedAxsome Therapeutics, Inc.
IndicationTreatment Resistant Major Depressive Disorder
Actual study completion2020-03-20
Phase
Phase2 / Phase3Study status
CompletedAxsome Therapeutics, Inc.
IndicationAgitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation,Psychomotor
Actual study completion2020-04-17
Phase
Phase2Study status
CompletedAxsome Therapeutics, Inc.
IndicationMajor Depressive Disorder
Actual study completion2019-01-07
Phase
Phase3Study status
CompletedAxsome Therapeutics, Inc.
IndicationDepression; Major Depressive Disorder
Actual study completion2019-12-05
Phase
Phase2Study status
CompletedAxsome Therapeutics, Inc.
IndicationTreatment Resistant Depression; Major Depressive Disorder
Actual study completion2021-07-30
Phase
Phase3Study status
CompletedAxsome Therapeutics, Inc.
IndicationAgitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation,Psychomotor
Actual study completion2022-11-21
Phase
Phase2Study status
UnknownAxsome Therapeutics, Inc.
IndicationMajor Depressive Disorder; Treatment Resistant Depression
Estimated study completion2021-07
Phase
Phase3Study status
CompletedAxsome Therapeutics, Inc.
IndicationAgitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation
Actual study completion2024-12-21
5 unverified sponsor matches remain unlinked.
No verified developments in tracked sources.